Neuralstem Inc. has received the green light to begin the first human stem cell trial to treat Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig’s disease. The company’s stock soared on the news.
Neuralstem has only received approval for the first stage of the trial that would consist of 12 patients who will receive stem cell injections in the lumbar area of the spinal cord.
Neuralstem said the trial will be under the direction of principal investigator Dr. Eva L. Feldman, Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery.
An estimated 400.000 Americans suffer from multiple sclerosis, but the findings of a new clinical trial shows promise in the fight to reverse symptoms of MS.
Researchers at Northwestern University conducted a trial using patients’ own stem cells to treat symptoms of multiple sclerosis, reports Early Show correspondent Debbye Turner Bell, and although the study group was small — only 21 patients participated in it — the findings are a huge breakthrough in the fight against MS.
Edwin McClure is strong and healthy now, but just four years ago, his life was very different.
“I would get fatigued. I couldn’t deal with
StemCells, Inc. announced today that the California Institute of Regenerative Medicine (CIRM) has approved the Company’s application for a “Disease Team Therapy Development Planning Award.”
The grant, totaling approximately $100,000, will help fund the Company’s plans to develop its proprietary human neural stem cell product, HuCNS-SC(R) cells, in Alzheimer’s disease by enabling the Company and its collaborators at the University of California, Irvine, to prepare and submit an application for a “Disease Team Therapy Development Research Award.”
The CIRM has indicated that each Research Award will be up to $20 million, payable over four years, to fund preclinical and IND-enabling activities
“More funds are necessary for research on amyotrophic lateral sclerosis (ALS). More resources to aid more serious and controlled research for cures that slow the degenerating effects of the disease, for example using stem cells”, said Claudio Sabelli, an ALS patient and member of the Board of the ‘Viva la Vita’ society, writing with a visually controlled computer that communicates for him, commenting about announcements on research to fight ALS.
Sabelli said, “As a patient, I have an opinion that is not supported by facts for the simple reason that there are no new developments. I